291 related articles for article (PubMed ID: 17558684)
1. Polycystic ovary syndrome and hyperprolactinemia are distinct entities.
Filho RB; Domingues L; Naves L; Ferraz E; Alves A; Casulari LA
Gynecol Endocrinol; 2007 May; 23(5):267-72. PubMed ID: 17558684
[TBL] [Abstract][Full Text] [Related]
2. [Macroprolactinemia in the differential diagnosis of hyperprolactinemia].
Toldy E; Löcsei Z; Szabolcs I; Kneffel P; Góth M; Szöke D; Kovács LG
Orv Hetil; 2003 Oct; 144(43):2121-7. PubMed ID: 14661444
[TBL] [Abstract][Full Text] [Related]
3. Prolactin secretion in polycystic ovary syndrome (PCOS).
Szosland K; Pawlowicz P; Lewiński A
Neuro Endocrinol Lett; 2015; 36(1):53-8. PubMed ID: 25789595
[TBL] [Abstract][Full Text] [Related]
4. Macroprolactinemia in women presenting with hyperandrogenic symptoms: Implications for the management of polycystic ovary syndrome.
Escobar-Morreale HF
Fertil Steril; 2004 Dec; 82(6):1697-9. PubMed ID: 15589886
[TBL] [Abstract][Full Text] [Related]
5. [Effect of hyperprolactinemia upon clinical symptoms of patients with polycystic ovary syndrome].
Wang Y; Hu ZP; Li MZ; Li R; Wang LN; Chen XN; Yang CS; Qiao J
Zhonghua Yi Xue Za Zhi; 2009 Oct; 89(37):2599-603. PubMed ID: 20137674
[TBL] [Abstract][Full Text] [Related]
6. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
[TBL] [Abstract][Full Text] [Related]
7. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
8. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
[TBL] [Abstract][Full Text] [Related]
9. Insulin response to oral glucose in healthy, lean young women and patients with polycystic ovary syndrome.
Kulshreshtha B; Ganie MA; Praveen EP; Gupta N; Lal Khurana M; Seith A; Dwivedi SN; Kumar G; Ammini AC
Gynecol Endocrinol; 2008 Nov; 24(11):637-43. PubMed ID: 19031221
[TBL] [Abstract][Full Text] [Related]
10. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
[TBL] [Abstract][Full Text] [Related]
11. [Responses of growth hormone and prolactin to L-Dopa in women with polycystic ovarian syndrome].
Wu X; Gu Q; Su Y
Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):489-91. PubMed ID: 9639745
[TBL] [Abstract][Full Text] [Related]
12. [Physiopathological link between polycystic ovary syndrome and hyperprolactinemia: myth or reality?].
Robin G; Catteau-Jonard S; Young J; Dewailly D
Gynecol Obstet Fertil; 2011 Mar; 39(3):141-5. PubMed ID: 21388855
[TBL] [Abstract][Full Text] [Related]
13. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
[TBL] [Abstract][Full Text] [Related]
14. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
[TBL] [Abstract][Full Text] [Related]
15. Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome.
Thomann R; Rossinelli N; Keller U; Tirri BF; De Geyter C; Ruiz J; Kränzlin M; Puder JJ
Gynecol Endocrinol; 2008 Apr; 24(4):199-206. PubMed ID: 18382906
[TBL] [Abstract][Full Text] [Related]
16. Body fat composition and distribution in women with polycystic ovary syndrome.
Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study.
Celik O; Sahin I; Celik N; Hascalik S; Keskin L; Ozcan H; Uckan A; Kosar F
Hum Reprod; 2007 Nov; 22(11):2992-8. PubMed ID: 17855407
[TBL] [Abstract][Full Text] [Related]
18. What is the optimal prolactin cutoff for predicting the presence of a pituitary adenoma in patients with polycystic ovary syndrome?
Kim SI; Yoon JH; Park DC; Yang SH; Kim YI
Int J Med Sci; 2023; 20(4):463-467. PubMed ID: 37057215
[No Abstract] [Full Text] [Related]
19. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
[TBL] [Abstract][Full Text] [Related]
20. Prolactin response to clomiphene citrate is different in hyperprolactinemic polycystic ovary syndrome and idiopathic hyperprolactinemia.
Lewinthal D; Corenblum B; Taylor PJ
Int J Fertil; 1987; 32(3):185-7, 191. PubMed ID: 2885281
[No Abstract] [Full Text] [Related]
[Next] [New Search]
